• Accueil >
  • Publications >
  • SigH stress response mediates killing of <i>Mycobacterium tuberculosis</i> by activating nitronaphthofuran prodrugs via induction of Mrx2 expression

SigH stress response mediates killing of <i>Mycobacterium tuberculosis</i> by activating nitronaphthofuran prodrugs via induction of Mrx2 expression

11 janv. 2023Nucleic Acids Research

DOI : 10.1093/nar/gkac1173

Auteurs

Laura Cioetto-Mazzabò, Francesca Boldrin, Claire Beauvineau, Martin Speth, Alberto Marina, Amine Namouchi, Greta Segafreddo, Mena Cimino, Sandrine Favre-Rochex, Seetha Balasingham, Beatriz Trastoy, Hélène Munier-Lehmann, Gareth Griffiths, Brigitte Gicquel, Marcelo E Guerin, Riccardo Manganelli, Noelia Alonso-Rodríguez

Résumé

Abstract

The emergence of drug-resistant Mycobacterium tuberculosis strains highlights the need to discover anti-tuberculosis drugs with novel mechanisms of action. Here we discovered a mycobactericidal strategy based on the prodrug activation of selected chemical derivatives classified as nitronaphthofurans (nNFs) mediated by the coordinated action of the sigH and mrx2 genes. The transcription factor SigH is a key regulator of an extensive transcriptional network that responds to oxidative, nitrosative, and heat stresses in M. tuberculosis. The nNF action induced the SigH stress response which in turn induced the mrx2 overexpression. The nitroreductase Mrx2 was found to activate nNF prodrugs, killing replicating, non-replicating and intracellular forms of M. tuberculosis. Analysis of SigH DNA sequences obtained from spontaneous nNF-resistant M. tuberculosis mutants suggests disruption of SigH binding to the mrx2 promoter site and/or RNA polymerase core, likely promoting the observed loss of transcriptional control over Mrx2. Mutations found in mrx2 lead to structural defects in the thioredoxin fold of the Mrx2 protein, significantly impairing the activity of the Mrx2 enzyme against nNFs. Altogether, our work brings out the SigH/Mrx2 stress response pathway as a promising target for future drug discovery programs.

Membres

CLAIRE BEAUVINEAU

Ingénieur de recherche CNRS